Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine-Reference-Cited by-同舟云学术

Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine

Published:2023-05-11 Issue:8 Volume:35 Page:753-759
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

D’Angelo Alberto¹²^ORCID,Catalano Martina³,Conca Raffaele⁴⁵,Petrioli Roberto⁶,Siminonato Francesca⁵,Cappetta Alessandro⁵,Roviello Giandomenico⁷,Ramello Monica⁸

Affiliation:

1. Department of Life Sciences, University of Bath, Bath, UK

2. Department of Oncology, Royal United Hospital, Bath, UK

3. School of Human Health Sciences, University of Florence, Florence, Italy

4. Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Vulture, Potenza, Italy

5. Department of Oncology, San Bortolo General Hospital, Vicenza, Italy

6. Department of Medicine, Surgery and Neurosciences, Medical Oncology Unit, University of Siena, Siena, Italy

7. Department of Health Sciences, University of Florence, Florence, Italy

8. Oncology Unit, Department of Medical, Surgical, & Health Sciences, University of Trieste, Trieste, Italy

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2023.2190712

Reference20 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Haeberle L Esposito I. Pathology of pancreatic cancer. Pathology of pancreatic cancer. Transl Gastroenterol Hepatol. 2019;4:50.

3. Treatment for potentially resectable exocrine pancreatic cancer. Last accessed Feb 2023 . https://www.uptodate.com/contents/treatment-for-potentially-resectable-exocrine-pancreatic-cancer

4. Validation of the 6th edition AJCC pancreatic cancer staging system

5. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer